Zobrazeno 1 - 10
of 535
pro vyhledávání: '"Ravi A Madan"'
Autor:
Tian Zhang, Nicholas J Vogelzang, Daniel P Petrylak, Ravi A Madan, Karen A Autio, Ray Li, Helen Cho, Szu-Yu Tang, Celestia S Higano, Luke Nordquist, Leonard J Appleman, Xin-Hua Zhu, Hani Babiker, Sandip M Prasad, Michael T Schweizer, Stephane Billotte, Nora Cavazos, Orlaith Bogg, Kam Chan, Megan Kaneda, I-Ming Wang, Jenny Zheng, Robert Hollingsworth, Kenneth A Kern
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 3 (2023)
Background This phase 1 study evaluated PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in two clinical states of prostate cancer (PC), metastatic castration-resistant PC (mCRPC) and biochemical recurrence (BCR).Methods For dose escal
Externí odkaz:
https://doaj.org/article/a4a8a3a078ab4567a1641ae4c2b5d1db
Autor:
Mohammad O. Atiq, Danielle M. Pastor, Fatima Karzai, Amy R. Hankin, Baris Turkbey, Lisa M. Cordes, Isaac Brownell, Yi Liu, Gregory T. Chesnut, Ravi A. Madan
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The risks of development of colorectal and endometrial cancers in individuals with Lynch syndrome (LS) are well known and have been widely studied. In recent years, the potential association of other malignancies, including prostate cancer, with LS h
Externí odkaz:
https://doaj.org/article/2cdfa97256cf466fb8839255a06eab2f
Autor:
Sungwon Lee, Daniel C. Elton, James L. Gulley, Perry J. Pickhardt, William L. Dahut, Ravi A. Madan, Peter A. Pinto, Deborah E. Citrin, Ronald M. Summers
Publikováno v:
Tomography, Vol 8, Iss 2, Pp 607-616 (2022)
Traditionally, atherosclerotic risk factors for cardiovascular disease and cancer are assessed using coronary artery calcium scoring. However, this neglects the impact of atherosclerotic disease more proximal to the cancer site. This study assesses w
Externí odkaz:
https://doaj.org/article/83477bcfd75b49519e6ddf7705112213
Autor:
Fatima Karzai, Ravi A. Madan
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 21 (2022)
Despite the clinical advances in managing metastatic prostate cancer in the last 20 years, treatments for patients with metastatic disease only offer a brief respite from disease progression, especially after first-line therapies. Research into treat
Externí odkaz:
https://doaj.org/article/55fa760f9da94a3a992a4762092f989e
Autor:
Samira Masoudi, Sherif Mehralivand, Stephanie A. Harmon, Nathan Lay, Liza Lindenberg, Esther Mena, Peter A. Pinto, Deborah E. Citrin, James L. Gulley, Bradford J. Wood, William L. Dahut, Ravi A. Madan, Ulas Bagci, Peter L. Choyke, Baris Turkbey
Publikováno v:
IEEE Access, Vol 9, Pp 87531-87542 (2021)
In this study, we formulated an efficient deep learning-based classification strategy for characterizing metastatic bone lesions using computed tomography scans (CTs) of prostate cancer patients. For this purpose, 2,880 annotated bone lesions from CT
Externí odkaz:
https://doaj.org/article/453e9898b0f745f984167e9d0caf9d9f
Autor:
Scott Wilkinson, Stephanie A. Harmon, Nicholas T. Terrigino, Fatima Karzai, Peter A. Pinto, Ravi A. Madan, David J. VanderWeele, Ross Lake, Rayann Atway, John R. Bright, Nicole V. Carrabba, Shana Y. Trostel, Rosina T. Lis, Guinevere Chun, James L. Gulley, Maria J. Merino, Peter L. Choyke, Huihui Ye, William L. Dahut, Baris Turkbey, Adam G. Sowalsky
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-8 (2020)
Prostate cancer is often a multifocal disease but how best to manage this clinically remains unclear. Here, the authors report a single case study of a patient with two genetically diverse tumours which showed differential response to therapy.
Externí odkaz:
https://doaj.org/article/abc0a61cbf274e5db9f8179a93bb5a6a
Autor:
Ravi A Madan, Christopher Heery, Claudia Palena, Caroline Jochems, Julius Strauss, Marijo Bilusic, Fatima Karzai, Jennifer L Marté, Charalampos Floudas, Peter J DeMaria, Katherine Lee-Wisdom, Angie Schwab, Jason Mark Redman, Eva Dombi, Brigitte Widemann, Borys Korchin, Tatiana Adams, Cesar Pico-Navarro
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Externí odkaz:
https://doaj.org/article/37a0f2d29a6c47d6940c4dc1bf5400ca
Autor:
Arun Rajan, Christopher R. Heery, Anish Thomas, Andrew L. Mammen, Susan Perry, Geraldine O’Sullivan Coyne, Udayan Guha, Arlene Berman, Eva Szabo, Ravi A. Madan, Leomar Y. Ballester, Stefania Pittaluga, Renee N. Donahue, Yo-Ting Tsai, Lauren M. Lepone, Kevin Chin, Fiona Ginty, Anup Sood, Stephen M. Hewitt, Jeffrey Schlom, Raffit Hassan, James L. Gulley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Abstract Background Thymic epithelial tumors are PD-L1–expressing tumors of thymic epithelial origin characterized by varying degrees of lymphocytic infiltration and a predisposition towards development of paraneoplastic autoimmunity. PD-1–target
Externí odkaz:
https://doaj.org/article/b66a3a1a163041f19fe2d792850a4a64
Autor:
Marijo Bilusic, Christopher R. Heery, Julie M. Collins, Renee N. Donahue, Claudia Palena, Ravi A. Madan, Fatima Karzai, Jennifer L. Marté, Julius Strauss, Margaret E. Gatti-Mays, Jeffrey Schlom, James L. Gulley
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-8 (2019)
Abstract Background HuMax-IL8 (now known as BMS-986253) is a novel, fully human monoclonal antibody that inhibits interleukin-8 (IL-8), a chemokine that promotes tumor progression, immune escape, epithelial-mesenchymal transition, and recruitment of
Externí odkaz:
https://doaj.org/article/df02368d4e9e4af5bd803ce31f37897d
Autor:
Fatima Karzai, David VanderWeele, Ravi A. Madan, Helen Owens, Lisa M. Cordes, Amy Hankin, Anna Couvillon, Erin Nichols, Marijo Bilusic, Michael L. Beshiri, Kathleen Kelly, Venkatesh Krishnasamy, Sunmin Lee, Min-Jung Lee, Akira Yuno, Jane B. Trepel, Maria J. Merino, Ryan Dittamore, Jennifer Marté, Renee N. Donahue, Jeffrey Schlom, Keith J. Killian, Paul S. Meltzer, Seth M. Steinberg, James L. Gulley, Jung-Min Lee, William L. Dahut
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Abstract Background Checkpoint inhibitors have not been effective for prostate cancer as single agents. Durvalumab is a human IgG1-K monoclonal antibody that targets programmed death ligand 1 and is approved by the U.S. Food and Drug Administration f
Externí odkaz:
https://doaj.org/article/0cf7309b04d14ab6b60eafc1dd43beb1